- Powerful automated protein sample prep can be leveraged by non-automation experts.
- Various sample prep workflows can be addressed with a small footprint automation platform.
- A single automation platform can be used across the entire drug discovery/development process in regulated and non-regulated labs.
- Analytical Scientists
- Biopharma Scientists
- Lab Managers
- Lab Directors
- Lab Analyst
Automated Protein Sample Prep in Regulated and Non-regulated Labs just got easier
Free Virtual Webinar
On Demand
About the Event
Biotherapeutic drug discovery and development is a long and expensive process that requires a wide variety of assays be performed at various stages of the process, at high and low throughput, and in both regulated and non-regulated environments. The time and expense required to develop new biotherapeutics is highly dependent on choosing the best drug candidates to move forward through this complex process. The ability to identify the best candidates is, in turn, highly dependent on the quality of the data generated from the assays that monitor the drug candidates' Critical Quality Attributes.
This presentation focuses on how automation can improve the probability of successfully and efficiently moving the best candidates through the development process by improving data quality, minimizing errors, reducing labor costs, and ensuring seamless transfer of assays between lab even when these labs have different regulatory requirements.
The AssayMAP Bravo is an automated microchromatography-based protein sample preparation platform that can be used to perform the assays required for the drug development process from target identification to manufacturing QC. This automation platform provides all the benefits of automation and is designed to be easy to use, enable walkup operation, come with pre-optimized applications for a wide variety of workflows, simplify documentation, and be used in both non-regulated and regulated (optional 21CFR part 11 enabling features) labs so it can be used across the entire drug development process.
Key Learnings:
Who Should Attend:
In Partnership With
